Omeros Corporation (OMER) Analysts See $-0.16 EPS

February 24, 2018 - By marketbeat

 Omeros Corporation (OMER) Analysts See $ 0.16 EPS
Investors sentiment increased to 2.86 in Q3 2017. Its up 1.59, from 1.27 in 2017Q2. It is positive, as 10 investors sold Omeros Corporation shares while 11 reduced holdings. 22 funds opened positions while 38 raised stakes. 22.04 million shares or 15.32% more from 19.11 million shares in 2017Q2 were reported.
California State Teachers Retirement System reported 71,201 shares. Chicago Equity Ptnrs Ltd Llc accumulated 195,875 shares or 0.13% of the stock. Asset holds 0.04% or 10,765 shares in its portfolio. Int Group holds 0% of its portfolio in Omeros Corporation (NASDAQ:OMER) for 27,917 shares. Stifel Corp stated it has 394,428 shares or 0.03% of all its holdings. Bessemer Gp stated it has 1,286 shares. Maryland-based Proshare Advsr Ltd Company has invested 0.01% in Omeros Corporation (NASDAQ:OMER). Eam Investors Ltd Company holds 0.58% of its portfolio in Omeros Corporation (NASDAQ:OMER) for 202,025 shares. State Of Wisconsin Invest Board reported 23,000 shares. Ingalls And Snyder Ltd Liability Company holds 5.16 million shares or 5.81% of its portfolio. National Bank & Trust Of America De invested 0% of its portfolio in Omeros Corporation (NASDAQ:OMER). Moreover, Financial Bank Of Montreal Can has 0% invested in Omeros Corporation (NASDAQ:OMER) for 45,563 shares. The Illinois-based Trust Department Mb Finance National Bank & Trust N A has invested 0.01% in Omeros Corporation (NASDAQ:OMER). Citadel Limited Liability accumulated 65,802 shares. Blackrock Inc holds 0% of its portfolio in Omeros Corporation (NASDAQ:OMER) for 3.93M shares.

Since January 3, 2018, it had 0 insider purchases, and 2 insider sales for $1.36 million activity. $1.34 million worth of stock was sold by Kelbon Marcia S. on Wednesday, January 3.

Analysts expect Omeros Corporation (NASDAQ:OMER) to report $-0.16 EPS on March, 15.They anticipate $0.04 EPS change or 20.00 % from last quarter’s $-0.2 EPS. After having $-0.07 EPS previously, Omeros Corporation’s analysts see 128.57 % EPS growth. The stock increased 11.11% or $1 during the last trading session, reaching $10. About 1.63 million shares traded or 89.65% up from the average. Omeros Corporation (NASDAQ:OMER) has risen 42.59% since February 24, 2017 and is uptrending. It has outperformed by 25.89% the S&P500.

Omeros Corporation (NASDAQ:OMER) Ratings Coverage

Among 9 analysts covering Omeros (NASDAQ:OMER), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Omeros had 26 analyst reports since August 10, 2015 according to SRatingsIntel. As per Tuesday, June 13, the company rating was maintained by Cantor Fitzgerald. The firm earned “Buy” rating on Wednesday, August 2 by Maxim Group. The firm earned “Buy” rating on Thursday, November 10 by Needham. The rating was initiated by Roth Capital with “Buy” on Monday, August 10. Cantor Fitzgerald maintained the stock with “Hold” rating in Thursday, August 24 report. The stock of Omeros Corporation (NASDAQ:OMER) earned “Buy” rating by Maxim Group on Tuesday, June 13. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, November 29 report. The stock of Omeros Corporation (NASDAQ:OMER) earned “Market Perform” rating by Cowen & Co on Thursday, November 2. As per Friday, June 3, the company rating was initiated by Cantor Fitzgerald. Wedbush maintained it with “Outperform” rating and $47 target in Wednesday, November 16 report.

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company has market cap of $480.04 million. The firm markets OMIDRIA for use during cataract surgery or intraocular lens replacement. It currently has negative earnings. The Company’s clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases.

Another recent and important Omeros Corporation (NASDAQ:OMER) news was published by Fool.com which published an article titled: “Here’s Why Omeros Corporation Is Getting Beaten Down on Wednesday” on February 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: